邹彤,杨杰孚

• 1:北京医院心内科

摘要(Abstract)：

<正>心力衰竭是心血管疾病终末期的常见综合征。随着人类寿命的延长,慢性心力衰竭的患病率日益增长。流行病学统计,美国人群的心力衰竭患病率为1.5%~2.0%,约有450万患者[1];中国成人的心力衰竭患病率约为0.9%,估计约有585万患者[2]。心力衰竭患者的病死率与严重程度相关,中、重度心力衰竭的5年病死率分别约为30%和50%。目前认为神经内分泌系统的激活是引起心肌细胞凋亡、心肌

关键词(KeyWords)： 心力衰竭;心脏再同步化治疗;埋藏式心脏复律除颤器

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 邹彤,杨杰孚

参考文献(References)：

• [1]Jessup M,Brozena S.Heart failure.N Engl J Med,2003,348:2007-2018.
• [2]顾东风,黄广勇,何江,等.中国心力衰竭流行病学调查及其患病率.中华心血管病杂志,2003,31:3-6.
• [3]The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med,1991,325:293-302.
• [4]Mc Murray JJ,Adamopoulos S,Anker SD,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC.Eur Heart J,2012,33:1787-1847.
• [5]Tomassoni G,Baker J,Corbisiero R,et al.Postoperative performance of the Quartet?left ventricular heart lead.J Cardiovasc Electrophysiol,2013,24:449-456.
• [6]Lau EW.Yoked catheter positioning in transseptal endocardial left ventricular lead placement.Pacing Clin Electrophysiol,2011,34:884-893.
• [7]Auricchio A,Delnoy PP,Butter C,et al.Feasibility,safety,and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients:results of the Wireless Stimulation Endocardially for CRT(Wi SE-CRT)study.Europace,2014,16:681-688.
• [8]Auricchio A,Delnoy PP,Regoli F,et al.First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system:novel endocardial left ventricular resynchronization therapy in heart failure patients.Europace,2013,15:1191-1197.
• [9]Moss AJ,Hall WJ,Cannom DS,et al.Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.Multicenter Automatic Defibrillator Implantation Trial Investigators.N Engl J Med,1996,335:1933-1940.
• [10]Bardy GH,Lee KL,Mark DB,et al.Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.N Engl J Med,2005,352:225-237.
• [11]Hohnloser SH,Kuck KH,Dorian P,et al.Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.N Engl J Med,2004,351:2481-2488.
• [12]Steinbeck G,Andresen D,Seidl K,et al.Defibrillator implantation early after myocardial infarction.N Engl J Med,2009,361:1427-1436.
• [13]Bardy GH,Smith WM,Hood MA,et al.An entirely subcutaneous implantable cardioverter defibrillator.N Engl J Med,2010,363:36-44.
• [14]Weiss R,Knight BP,Gold MR,et al.Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator.Circulation,2013,128:944-953.
• [15]Aziz S,Leon AR,El-Chami MF.The subcutaneous defibrillator:a review of the literature.J Am Coll Cardiol,2014,63:1473-1479.
• [16]Majithia A,Estes NA 3rd,Weinstock J.Advances in sudden death prevention:the emerging role of a fully subcutaneous defibrillator.Am J Med,2014,127:188-194.
• [17]Akerstrm F,Arias MA,Pachón M,et al.Subcutaneous implantable defibrillator:State-of-the art 2013.World J Cardiol,2013,5:347-354.
• [18]Sanders WE Jr,Richey MW,Malkin RA,et al.Novel intravascular defibrillator:defibrillation thresholds of intravascular cardioverter-defibrillator compared to conventional implantable cardioverter-defibrillator in a canine model.Heart Rhythm,2011,8:288-292.
• [19]Neuzil P,Reddy VY,Merkely B et al.Implantable intravascular defibrillator:defibrillation thresholds of an intravascular cardioverter-defibrillator compared with those of a conventional ICD in humans.Heart Rhythm,2014,11:210-215.
• [20]Merkely B,Geller L,Molnar L,et al.Intravascular defibrillator(Inner Pulse PICD):implantation and removal techniques.Pacing Clin Electrophysiol,2011,34:1414-1415.
• [21]Kadish A,Nademanne K,Volosin K,et al.A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure.Am Heart J,2011,161:329-337.
• [22]Borggrefe M,Burkhoff D.Clinical effects of cardiac contractility modulation(CCM)as a treatment for chronic heart failure.Eur J Heart Fail,14:703-712.
• [23]Yu CM,Chan JY,Zhang Q,et al.Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling.JACC Cardiovasc Imaging,2:1341-1349.
• [24]De Ferrari GM,Crijns HJ,Borggrefe M,et al.Chronic vagus nerve stimulation:a new and promising therapeutic approach for chronic heart failure.Eur Heart J,2011,32:847-855.
• [25]Dicarlo L,Libbus I,Amurthur B,et al.Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms:the ANTHEM-HF study.J Card Fail,2013,19:655-660.
• [26]Liu Y,Yue WS,Liao SY,et al.Thoracic spinal cord stimulation improves cardiac contractile function and myocardial oxygen consumption in a porcine model of ischemic heart failure.J Cardiovasc Electrophysiol,2012,23:534-540.
• [27]Lopshire JC,Zhou X,Dusa C,et al.Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model.Circulation,2009,120:286-294.
• [28]Jesus S,Alo KM,Torre-Amione G.Initial Experience with Spinal Cord Stimulation(SCS)for the Treatment of Advanced Heart Failure.J Cardiac Failure,2010,16:S67.